KVUE
Kenvue Inc.NYSEConsumer DefensiveAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
22.35
PEG
0.52
P/B
3.05
P/S
2.17
EV/EBITDA
13.62
DCF Value
$37.06
FCF Yield
5.2%
Div Yield
4.8%
Margins & Returns
Gross Margin
58.1%
Operating Margin
17.9%
Net Margin
9.7%
ROE
13.9%
ROA
16.6%
ROIC
8.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.78B | $330.0M | $0.17 |
| FY 2025 | $15.12B | $1.47B | $0.76 |
| Q3 2025 | $3.76B | $398.0M | $0.21 |
| Q2 2025 | $3.84B | $420.0M | $0.22 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Consumer Defensive
Industry
—
Country
US
Exchange
NYSE
Beta
0.57
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.